An observational study in Group B Streptococcus Carrier in Childbirth, Group B Streptococcal Infection, Late-Onset and Group B Streptococcal Infection, Early-Onset, sponsored by St George's, University of London. Recruiting at 6 sites in 6 countries. Open to participants aged Up to 90 Days. Per ClinicalTrials.gov, last updated 2023-10-26.
Sponsored by St George's, University of London · Observational
A multicentre, international case-control study to develop a biobank of sera from 150 cases of serotype III GBS disease and associated clinical information from seven countries (Malawi, Uganda, UK, the Netherlands, Italy and France), with 3:1 (450) serotype matched healthy controls.
Group B Streptococcus (GBS) causes severe infections in young infants across the world. In 2015 it was estimated that there were at least 319,000 infants under three months of age with GBS disease worldwide, resulting in 90,000 deaths and at least 10,000 children with long term disabilities. Around 20% of all pregnant women carry GBS in their vagina and bowel, and babies are exposed to GBS bacteria around the time of birth. The options for prevention are currently limited to offering antibiotics during labour.
A vaccine that could be given to pregnant women has the greatest potential to benefit mothers and babies worldwide. There are vaccines currently being tested in clinical trials, including in pregnant women. Given the complexity, size and costs associated with a phase III trial, it is generally agreed that indirect evidence (correlates) of protection (CoP), based on immunologic data from vaccine and seroepidemiological studies, opsonophagocytic assays and supported by animal models, could be pivotal for vaccine licensure, with effectiveness subsequently confirmed in post-licensure evaluations.
This study aims to develop a biobank of sera from 150 cases of serotype III GBS disease and associated clinical information from seven countries (Malawi, Uganda, UK, the Netherlands, Italy and France) with 3:1 (450) serotype matched healthy controls.
GBS cases will be identified through active surveillance of GBS disease in infants, as part of ongoing epidemiological studies in Uganda, the UK, Italy, France, the Netherlands and Malawi. Upon identification of cases, consent will be requested to obtain a serum sample (1-2 mL of blood collected from infant), the GBS isolate and to collect brief clinical and demographic details. Each site will aim to collect around 50 cases of invasive GBS disease cases (with all samples) over the course of 2 years.
Each site will also recruit approximately 1000 women to have a rectovaginal swab at 35-37 weeks gestation and cord and maternal blood samples at delivery. These women and their infants will be followed up to 90 days of age and considered appropriate controls if the infants are exposed to the same serotype/strain of GBS at delivery as the case - but do not develop GBS the first 90 days of life. We will select 3 controls for every case.
The biorepository will be established at the St George's University of London for all samples from the European Union and Malawi and the MRC/UVRI \& LSHTM Uganda Research Unit for Ugandan samples.
146 studies on the registry are indexed under Streptococcal Infections; 14 are open to participants now.
This study's planned enrollment of 600 is above the median of 400 across 31 observational studies indexed under Streptococcal Infections.
Browse Streptococcal Infections studies →St George's, University of London is the lead sponsor of 106 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study will enroll infant subjects from the general population who are delivered at one of the six hospital sites.
Inclusion Criteria:
Cases:
Infant 0-90 days of life with GBS identified from a normally sterile site.
Controls:
Healthy infant born to a GBS colonised woman that does not develop GBS disease between birth and 90 days of life.
Exclusion Criteria An infant is not eligible unless a parent/person with parental responsibility gives .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
150 infants with invasive serotype III GBS disease (isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
450 infants exposed to serotype III GBS at birth - but who do not develop invasive GBS disease in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
To establish a biobank of at least 150 GBS serotype III cases including both the isolate and associated maternal and infant serum.
Biobank at St George's, University of London
Time frame: Over the course of 2 years
To determine the quantity of antibody associated with protection against GBS disease
Geometric mean and median antibody titres will be calculated for cases and controls and comparisons made as appropriate
Time frame: Over the course of 2 years
To determine the functional antibody associated with protection against GBS disease.
Samples will be tested using opsonophagocytosis killing assay for both anti-capsular and anti-protein antibodies.
Time frame: Over the course of 2 years
To demonstrate the relationship between antibody quantity and function in protection against GBS disease
To directly compare total antibody concentration titers (measured by multiplex LUMINEX) with opsonophagocytosis from functional antibodies at the time of birth and at the time of disease.
Time frame: Over the course of 2 years
To refine estimates for serocorrelates of protection against GBS disease.
To provide initial data on the relationship between antibody and invasive GBS disease risk by estimating the odds ratio of invasive GBS disease for antibody concentrations above various thresholds for STIII
Time frame: Over the course of 2 years
To provide training to participating African laboratories to assure the quality of sample collection and data curation.
A South-South partnership between Makerere University John Hopkins Research Collaboration (MUJHU),and Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) to optimise the capacity for conducting clinical trials for maternal immunisation in Sub-Saharan Africa
Time frame: Over the course of 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2020 (actual). Primary completion is estimated for Mar 2024, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St George's, University of London →